Saturday, April 04, 2020 5:13:47 AM
“We are excited to have Aileen join us and strengthen our leadership team’s core capabilities, as her strategic track record and vast industry network will add tremendous value to the organization”, commented Harel Gadot, CEO, President and Chairman. “Her proven experience in merger and acquisition transactions as well as the formation and execution of strategic collaborations across the industry, will greatly enhance the Company’s ability to achieve its strategic growth objectives.”
During her almost 30 years at Johnson & Johnson, Ms. Stockburger held several business development and finance roles in Medical Devices, Corporate and Consumer. She served as Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities. While in that role, she played leading and significant roles in over $70 billion worth of transactions, including: Johnson and Johnson’s acquisition of Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining Johnson & Johnson, Aileen spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania
“Throughout my career I have sought out opportunities that allow me to use my specific skills to help effect meaningful change and impact to the healthcare market,” commented Ms. Stockburger. “I have watched Microbot Medical the past few years, albeit from a distance, and my enthusiasm to join the Board at this specific time is due to its progress developing highly advanced and revolutionary robotic systems that will transform the future of healthcare. I believe that my expertise, combined with Microbot’s assets and ambition, will allow us to address new and emerging growth markets.”
Recent MBOT News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 12:10:21 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 12:07:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:33:51 PM
- Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up • GlobeNewswire Inc. • 09/30/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 12:30:27 PM
- Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System • GlobeNewswire Inc. • 09/17/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 05:00:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/22/2024 03:36:31 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/22/2024 03:33:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 12:30:38 PM
- Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/15/2024 11:34:05 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/15/2024 11:32:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 05:15:42 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 08:30:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 08:30:46 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 08:30:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:30:38 PM
- Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization • GlobeNewswire Inc. • 08/13/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:30:27 PM
- Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System • GlobeNewswire Inc. • 08/01/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/19/2024 11:46:05 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/19/2024 11:43:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/19/2024 11:40:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 12:30:37 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM